Recbio

Recbio is a Chinese innovative vaccine company that was founded in 2012. The company's slogan, "Protect Human Health with Best-in-Class Vaccines," epitomizes its mission. To achieve its vision of becoming a leader in innovative vaccine development, Recbio has established three cutting-edge technology platforms: a novel adjuvants platform, protein engineering platform, and immunological evaluation platform. The company boasts a high-value vaccine portfolio comprising recombinant protein, HPV, COVID-19, shingles, influenza, and adults TB vaccine candidates. Notably, Recbio's scientific team brings more than 20 years of experience in developing and commercializing innovative vaccines. This expertise has propelled Recbio to secure a CNY 1.00B Series C investment on 14th June 2021. The investment was made by a prestigious group of investors including Legend Capital, Temasek Holdings, Boyu Capital, LYFE Capital, Sequoia China, E Fund Management Co., LTD., and Lake Bleu Capital. For more information, please visit Recbio's website.